>340
GMP batches released
>50
Audits completed
>30
Process development projects
>70
Qualified assays and methods
About Oxford Biomedica
We believe in pushing the boundaries of scientific possibility and know it takes exceptional knowledge and innovative processes to make that happen.
- 1st worldwide to administer lentiviral vector gene therapy in vivo
- 1st commercial supplier of lentiviral vectors for a CAR-T therapy
AAV platform
Bring confidence to clinical trials with our proven AAV viral vector development and production process, capable of producing consistently high quality and high titre products.
We have:
- Demonstrated >E15 vg/L titers
- Achieved >90% fully intact vector
- Analytical toolbox with over 45 methods
- Process scales from 2L to 2000L
- Six successful IND/CTA filings
Tech transferred-in
Alongside our own LentiVector® and AAV platform technologies, we have the facilities and expertise to fulfil almost any development need. You define the methods and processes, and we leverage our class-leading capabilities as appropriate.
Latest news
Discover our latest updates.
Oxford Biomedica Provides Update on CDMO Services Including New Commercial Agreement
Oxford, UK – 20, March, 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today provides an update on its CDMO services activity. – New and expanded contracts highlight commercial momentum across all viral vector types – OXB now working on multiple late-stage programmes with its portfolio of client programmes progressing to later stage work Year to date, Oxford Biomedica has experienced consistently strong demand for its CDMO services across all key viral vector types, with its portfolio of client programmes transitioning towards later stage work. As a result of commercial developments set out below, OXB is now working on three late-stage programmes. Recently, the Company signed a contract with a new undisclosed US-based biotechnology company for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T programme targeting multiple myeloma. Manufacturing will take place in Oxbox, the Company’s Oxford based manufacturing facility. Alongside this, Oxford Biomedica has signed two new programmes with existing clinical-stage clients for projects including Process Development and GMP manufacturing. Furthermore, the Company has signed a new agreement with a US-based client specialising in cardiac gene therapy for the tech transfer, optimisation and manufacture of an adeno-associated virus-based process (AAV). Under the terms of these agreements, Oxford Biomedica will receive payments related to the development and manufacturing of viral vectors for use in clinical trials in addition to certain development and regulatory milestone payments. These payments will support the Company in achieving its medium-term financial guidance announced on 5 March 2024. Dr Sébastien Ribault, Chief Commercial Officer of Oxford Biomedica, commented: “The signing of a late-stage programme, alongside the continued expansion of existing agreements since the start of 2024, demonstrates clients’ confidence in OXB’s ability to deliver process development and GMP manufacturing services. Our Business Development team continues to experience strong demand for process characterisation, validation, and process performance qualification (PPQ) work, showcasing the high quality and reliability of our services. This demand is in line with our forecasts across all key vectors and geographies, validating our growth strategy. We remain confident about our future prospects as the leading global pure-play CDMO in cell and gene therapy and our ability to continue building our client portfolio.” -Ends- Enquiries: Oxford Biomedica plc: Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com Mary-Jane Elliott / Matthew Neal / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy contract development and manufacturing organisation (CDMO) with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
Read moreBoard changes following transformation to pure-play CDMO business model
Oxford, UK – 11 March 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that CDMO expert, Peter Soelkner, will join the Board as a Non-Executive Director, effective from 15 March 2024. Concurrently, as part of Oxford Biomedica’s transformation into a pure-play CDMO, the Company announces that Catherine Moukheibir and Dr. Michael Hayden have informed the Board that they do not intend to stand for re-election at the upcoming Annual General Meeting in June 2024. Dr. Michael Hayden will continue to be an adviser to the Science and Technology Advisory Committee. Peter Soelkner has more than 30 years’ experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma, a global Aseptic Filling and Packaging CDMO, where over the past 15 years he has helped grow revenues from $200 million to more than $1 billion. Prior to Vetter, Mr. Soelkner held various senior positions at Sartorius including Vice President of the Americas region where he expanded the global footprint of the business across the US and multiple sectors. He has an MBA from Columbia Business School, New York and Masters in Chemical Engineering from TU Dortmund University, Germany. Dr. Roch Doliveux, Non-Executive Chairman of Oxford Biomedica, commented: “Alongside OXB’s transformation to become a pure-play viral vector CDMO, the Board of Directors has reviewed its breadth of skills and taken the decision to streamline the Board whilst bolstering its CDMO expertise. In light of this, we are delighted to welcome Peter Soelkner given his impressive track record in significantly growing Vetter, a leading global CDMO from $200m to more than $1bn in revenues. In parallel, Catherine Moukheibir and Dr. Michael Hayden, who have played a defining role in shaping OXB’s new strategy, both volunteered not to stand for re-election at the next AGM given that their strengths lie more in therapeutics rather than CDMO. I would like to personally thank Catherine and Michael for their impeccable service, loyalty and valuable insights.” Peter Soelkner commented: “I am pleased to be joining this innovative, client-centric, global business at such an exciting juncture in the Company’s journey. In my view Oxford Biomedica is extremely well-positioned as a pure-play CDMO and I am excited to apply my skillset and experience to help deliver the strategy to clients, enabling them to deliver life-changing therapies to patients.” Relevant disclosures There are no disclosures required to be made in accordance with LR 9.6.13R. -Ends- Enquiries: Oxford Biomedica plc: Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com Mary-Jane Elliott / Matthew Neal / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy contract development and manufacturing organisation (CDMO) with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
Read moreUpdate to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
Oxford, UK – 5 March 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today provides an update to its medium-term financial guidance following the recent completion of its acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“the Transaction”), as well as an update on trading for the year ended 31 December 2023. Additionally, the Company announces that it will report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024. – Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30% – Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmes – FY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim Results – FY2023 Preliminary Results to be reported on Monday, 29 April 2024 Trading update for FY2023 and updated medium-term financial guidance In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately £90 million. Operating EBITDA loss for the second half of 2023 is on track to be approximately £10 million better than the first half, as previously guided. As a result of the Transaction, including the additional revenues expected from the Company’s recently acquired operations in France, revenues for the year ended 31 December 2024 are expected to be between £126 million and £134 million, with revenues for the year being second half-weighted. Furthermore, the Company now expects a three-year revenue CAGR of more than 35% for the years 2023-2026, exceeding the previously communicated figure of more than 30%. Following the completion of the Company’s streamlining efforts in 2023, including the transition to a global site-based model, Oxford Biomedica reiterates its guidance of achieving broadly breakeven EBITDA in 2024, excluding the impact of the Transaction. Including the impact of the Transaction, the Company anticipates a modest operating loss attributed to the recently acquired French operations. This is expected to be fully funded by the €10 million cash funding in ABL Europe from Institut Mérieux received prior to completion of the Transaction. The Company confirms that it expects to achieve Operating EBITDA margins in excess of 20% by the end of 2026, as previously guided, and to be profitable on an EBITDA level in 2025. Liquidity update post ABL Europe acquisition The cash position at 31 December 2023 was £103.7 million. This excludes the €10 million cash funding in ABL Europe provided by Institut Mérieux upon completion of the Transaction on 29 January 2024. Post completion of the Transaction, Institut Mérieux SA became a 6.2% shareholder. Institut Mérieux will increase their shareholding upon the issuance of new shares pursuant to the subscription agreed as part of the Transaction, which was cash neutral for OXB. As previously disclosed in the announcement on 20 September 2023, this tranche of funding will provide the Company with €20 million to cover capital expenditure and potential operational losses related to the acquisition of ABL Europe, in exchange for Oxford Biomedica ordinary shares. The shares will be issued prior to 27 September 2024, with timing at Oxford Biomedica’s discretion, at a price being the 30-day VWAP to the day before the date of this subscription. Continued growth in orderbook for CDMO services Throughout 2023, OXB continued to grow and diversify its portfolio of clients and programmes with multiple expanded and new agreements signed for the development and manufacture of lentivirus, AAV and adenoviral vectors as well as other vector types. The contracted value of client orders signed during the year ended 31 December 2023 was £131 million, an increase of more than 50% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing). This increase reflects the improved biotech funding environment, which further instils confidence in the Company’s ability to further expand its backlog and receive orders. Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “OXB is continuing to successfully deliver its pure-play CDMO strategy. Our expansion into the European Union through the acquisition of ABL Europe strengthens our vector-agnostic service offering and strongly demonstrates our commitment to global client service and excellence. With these developments and our growing order book, we are confident about accelerating our financial performance and fulfilling our updated medium-term guidance.” Notice of Preliminary Results OXB expects to report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024. A briefing for investors and analysts will take place at 13:00 BST / 08:00 ET at One Moorgate Place, London, EC2R 6EA. -Ends- Enquiries: Oxford Biomedica plc: Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Consilium: T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com Mary-Jane Elliott / Matthew Neal / Davide Salvi About Oxford Biomedica Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy contract development and manufacturing organisation (CDMO) with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
Read moreDownloads
Learn about our 4th generation lentiviral vector delivery system and how this latest lentiviral vector technology developed at Oxford Biomedica can significantly enhance the development and manufacture of safer and more effective lentiviral vector based.
You can also download brochures for our other unique technologies including our TRiP System™ and LentiStable™ cell lines here.
